Vascular involvement in chronic kidney disease - mineral and bone disorder;Cévní postižení při minerá lové a kostní nemoci u chronického onemocnění ledvin

Osteologicky Bulletin

Volumn 13, Issue 4, 2008, Pages 166-171

  Zahalkova J ^a,b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Atherosclerosis; Calcification inhibitors; Chronic inflammation; Chronic kidney disease; Mineral and bone disorder; Vascular smooth muscle cell osteochondral transformation and mineralization

Indexed keywords

CALCIUM; FETUIN A; OSTEOGENIC PROTEIN 1; PHOSPHORUS;

ARTERIOSCLEROSIS; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MINERALIZATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; HUMAN; METABOLIC DISORDER; MINERAL BALANCE; MORBIDITY; MORTALITY; OSTEOCHONDRITIS DISSECANS; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; REVIEW; SMOOTH MUSCLE FIBER; SOFT TISSUE CALCIFICATION; VASCULAR SMOOTH MUSCLE;

EID: 60549102117     PISSN: 12113778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1946-1963.
2. Rodriguez-Garcia M, Naves M, Cannata-Andia J. Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J Nephrol 2005;18:458-463.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
4. Tentori F, Blavney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practise Patterns Study (DOPPS). Am J Kidney Dis 2008; 52(3):519-530.
5. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013.
6. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74:148-157.
7. Dusilová Sulková S. Mimokostní manifestace poruchy fosfokalciového metabolis-mu. Ve: Dusilová Sulková S, Bartůňková J, Bubeníček P, Fořtová M, Hájková B, Horáček J, Křížová H, Povýšl C, Smržova J, Sochorová K, Uhrová J, Válek M, Zima T. Renální osteopatie. Maxdorf 2007:55-61.
8. Lomashvili K, Garg P, O'Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 2006; 69:1464-1470.
9. Gotch F. Calcium and Phosphorus Kinetics in Hemodialysis Therapy. In: Ronco C, Cruz DN, eds: Hemodialysis, From Basic Research to Clinical Trials. Karger 2008: 210-214.
10. Shanahan CM. Mechanism of vascular calcification in renal disease. Clin Nephrol 2005, 63: 146-157.
11. Ketteler M, Giachelli C. Novel insight into vascular calcification. Kidney Int 2006;70, Suppl 105:S5-S9.
12. Neven E, Dauwe S, DeBroe ME, D(Haese PC, Persy V. Endochondral bone formation is involved in media calcification in rats and in man. Kidney Int 2007, 72:574-581.
13. Chen NX, O(Neill KD, Duan D. Phosphorus and uremic serum up-regulate oste-opontin expression in vascular smooth muscle cells. Kid Int 2002, 62: 1724-1731.
14. Moe SM, Duan D, Slehle BP et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kid Int 2003, 63: 1003-1011.
15. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralisation in vitro. Kidney Int 2004;66:2293-2299.
16. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-2867.
17. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM. Exploring the biology of vascular calcification in chronic kidney disease: What(s circulating? Kidney Int 2008;73:384-390.
18. Schurgers LJ, Teunissen KJ, Knapen MH. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005;25:1629-1633.
19. O'Neill WC. Vascular calcification: Not so crystal Clear. Kidney Int 2007;71: 282-283.
20. Schoppet M, Shanahn CM. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure, Kidney Int 2008,73:989-991.
21. Lomashvili KA, Garg P, Narisawa S, Milan JL, 0(Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008,73:1024-1030.
22. Verberckmoes SC, Persy V, Behets GJ, Neven E, Hufkens A, Zeber-Gong H, Miller D, Haffner D, Querfeld V, Bohic S, Debrroe ME, D'Haese PC. Uremia-related vascular calcifications: More than apatite deposition. Kidney Int 2007; 71:298-303.
23. Price PA, Lim JE. The inhibition of calciumphosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003; 278:22144-22152.
24. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross sectional study. Lancet 2003;361:827-833.
25. Osada M, Tian W, Horouchi H et al. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 2005;116:146-151.
26. Tsirpanlis G. Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? Blood Purif 2007; 14: S305-309.
27. London GM. Cardiovascular calcification in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;14:S305-309.
28. Špác J. Hypertenze a vlastnosti arteriální stěny. Kardiofórum 2006;4:9-13.
29. Kaupilla LI, Polak JF, Cupples A, Hannan MT, Kiel DP, Wilson PWK. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta. A 25-year follow-up study. Atherosclerosis 1997;132:245-250.
30. Muntner P, Ferramosca E, Bellasi A, Block GA, Raggi P. Development of a cardiovascular calcification index using simple imaging tools in haemodialysis patients. Nephrol Dial Transplant 2007;22:508-514.
31. Blacher J. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
32. Agatston AS, Janowitz WR, Hildner FJ. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-832.
33. Olgaard K. Clinical guide to bone and mineral metabolism in CKD. Ve: London M, Raggi P, Hruska KA Vascular calcification in CKD. National Kidney Foundation 2006,93-107.
34. Olgaard K. Clinical guide to bone and mineral metabolism in CKD. Ve: Drüeke TB, Moe SM, Langman CB. Treatment approaches in CKD. National Kidney Foundation 2006; 111-137.
35. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcifications in hemodialysis patients. Kidney Int 2002;62:245-252.
36. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindberg J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-1824.
37. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.
38. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Cha-san-Taber S, Diplom MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-1137.
39. Quinibi W, Moustafa M, Menz LR et al. Al-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2(CARE-2)study. Am J Kidney Dis 2008;51:952-965.
40. Block GA, Zdiv S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinski DA Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23:2311-2318.
41. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriquez M. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006;17:795-804.
42. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008;73:300-307.